论文部分内容阅读
目的:探讨盐酸替罗非班对非ST段抬高急性冠状动脉综合征(NSTE-ACS)患者冠状动脉介入治疗(PCI)术后C反应蛋白(CRP)、心肌标志物肌酸激酶同工酶(CK-MB)及肌钙蛋白(TnI)、出血事件的影响。方法:将NSTE-ACS患者PCI术后随机分为替罗非班组(50例)和对照组(50例),术前及术后测定CRP、CK-MB、TnI水平,并随访出血事件。结果:与对照组相比,替罗非班组PCI术后明显减低了CRP水平(P<0.05);未影响CK-MB、TnI水平(P>0.05);未增加出血事件(P>0.05)。结论:盐酸替罗非班对NSTE-ACS患者在PCI术后能够发挥抗炎作用;没有影响血清CK-MB、TnI水平;临床使用安全。
Objective: To investigate the effects of tirofiban hydrochloride on C-reactive protein (CRP), myocardial marker creatine kinase (MBK) isoenzyme in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) (CK-MB) and troponin (TnI), the impact of bleeding events. Methods: The patients with NSTE-ACS were randomly divided into tirofiban group (50 cases) and control group (50 cases). The levels of CRP, CK-MB and TnI were measured preoperatively and postoperatively, and the bleeding events were followed up. Results: Compared with the control group, the levels of CRP in the tirofiban group were significantly decreased (P <0.05); the levels of CK-MB and TnI were not affected (P> 0.05); no bleeding events were increased (P> 0.05). Conclusion: Tirofiban hydrochloride can exert anti-inflammatory effects on patients with NSTE-ACS after PCI and has no effect on serum CK-MB and TnI levels. It is safe in clinical use.